ReviewMolecular brain2026
The role of TRPV4 in ischemic stroke.
Review in Molecular brain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent advances in mechanotransduction research have highlighted the important role of mechanosensitive ion channels, particularly the transient receptor potential vanilloid 4 (TRPV4) channel. TRPV4, a non-selective cation channel predominantly located on the plasma membrane, is widely expressed in the mammalian and human brain and exhibits sensitivity to mechanical stimuli due to its unique structural features. Emerging evidence suggests that TRPV4 may function as a modulator in the pathophysiology of ischemic stroke. During the acute phase of stroke, TRPV4 activation has been linked to neuronal injury and cerebral edema. In contrast, during the recovery phase following ischemia-reperfusion, TRPV4 appears to contribute to neurovascular remodeling by facilitating intracranial arterial dilation and collateral vessel formation. These phase-dependent roles indicate that targeted modulation of TRPV4, particularly through physical therapies, could represent a potential therapeutic strategy to improve outcomes after ischemic stroke. This review summarizes current findings on TRPV4 in stroke pathobiology and discusses its potential as a mechanotherapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.